Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Published byGervais O’Connor’ Modified over 6 years ago

Similar presentations

Presentation on theme: "Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4."— Presentation transcript:

1 Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies.
Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Various complementary mechanisms may account for the clinical activity of blockade of the PD-1–PD-L1 axis or CTLA-4 inhibitory receptors. Only antibodies with isotypes activating Fc receptors on macrophages or NK cells, such as ipilimumab, are able to mediate ADCC (ie, IgG1 isotype). Anti-PD-1 and anti-CTLA-4 antibodies reverse inhibitory signals transmitted to T cells and allow metabolic reprogramming of T cells. Reverse signalling of PD-L1 on tumour cells may also be affected by blocking the PD-L1–PD-1 interaction. ADCC, antibody-dependent cellular cytotoxicity. Clemence Granier et al. ESMO Open 2017;2:e000213 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4."

Similar presentations

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New  Anagha Bangalore Kumar, MBBS, Rachel Maus, PhD,

Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New  Anagha Bangalore Kumar, MBBS, Rachel Maus, PhD,
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 4 Combination immunotherapeutic approaches with imatinib
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Hiding in Plain Sight: How Cancer Evades the Immune System

Hiding in Plain Sight: How Cancer Evades the Immune System
Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Figure 2 Site of action of checkpoint inhibitors and agonists being

Figure 2 Site of action of checkpoint inhibitors and agonists being
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.

Similar presentations

Ads by Google